Ex vivo lung perfusion
- PMID: 34992839
- PMCID: PMC8662477
- DOI: 10.21037/jtd-2021-23
Ex vivo lung perfusion
Abstract
Lung transplantation is a life-saving treatment for patients with end stage lung disease. The imbalance between lung graft supply and recipients has been a serious issue and barrier to successful lung transplantation. Ex vivo lung perfusion is a strategy wherein lungs are perfused and ventilated outside of the body. This technology has emerged as a safe preservation method that also enables the reassessment and reconditioning of marginal lung grafts. Ex vivo lung perfusion has successfully expanded the donor pool and led to greater lung transplant activity worldwide. Furthermore, ex vivo lung perfusion can be used as a platform for advanced diagnostics that enable specific targeted or personalized treatments that can be developed along a bench to bedside pathway leading to safe ex vivo intervention. Recent findings have shown that ex vivo lung perfusion could significantly and safely extend the preservation period, which enables transplant programs further optimization of the logistics around transplantation surgeries, and create a new paradigm whereby donor lungs are assessed at a centralized ex vivo lung perfusion center prior to delivery to a transplant clinic in need. The introduction of ex vivo lung perfusion to clinical lung transplantation has been a major step in the evolution and practice of lung transplantation.
Keywords: Ex vivo lung perfusion; donation after cardiocirculatory death donor; extended criteria donor.
2021 Journal of Thoracic Disease. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/jtd-2021-23). The series “Lung Transplantation: Past, Present, and Future” was commissioned by the editorial office without any funding or sponsorship. MC is a co-founder of XOR Labs Toronto Inc., a company dedicated to the development of EVLP machines. The XOR EVLP machine was not used in the performance of this study. SK reports grants from XVIVO Perfusion, personal fees from United Therapeutics/Lung Bioengineering, during the conduct of the study; and SK is a co-founder of XOR Labs Toronto Inc., a company dedicated to the development of EVLP machines. The XOR EVLP machine was not used in the performance of this study. SK is the co-founder and Chief Scientific Officer of Perfusix Canada Inc. The authors have no other conflicts of interest to declare.
Figures
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources